No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients

References

• Youlden DR, Cramb SM, Dunn NA, Muller JM, Pyke CM, Baade PD. The descriptive epidemiology of female breast cancer: An international comparison of screening, incidence, survival and mortality. Cancer Epidemiol 2012;36: 237–48.
   PubMed Web of Science ®Google Scholar
• National Board of Health and Welfare. Cancer i Siffror 2009 (Information about cancer incidence and survival in Sweden). 2009.
   Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group E. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687–717.
   PubMed Web of Science ®Google Scholar
• Lash TL, Lien EA, Sorensen HT, Hamilton-Dutoit S. Genotype-guided tamoxifen therapy: Time to pause for reflection?. Lancet Oncol 2009;10:825–33.
   PubMed Web of Science ®Google Scholar
• Hertz DL, McLeod HL, Irvin WJ, Jr. Tamoxifen and CYP2D6: A contradiction of data. Oncologist 2012;17: 620–30.
   PubMed Web of Science ®Google Scholar
• Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30–9.
   PubMed Web of Science ®Google Scholar
• Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006;80: 61–74.
   PubMed Web of Science ®Google Scholar
• Margolin S, Lindh JD, Thoren L, Xie H, Koukel L, Dahl ML, et al. CYP2D6 and adjuvant tamoxifen: Possible differences of outcome in pre- and post-menopausal patients. Pharmacogenomics 2013;14:613–22.
   PubMed Web of Science ®Google Scholar
• Wegman P, Vainikka L, Stål O, Nordenskjöld B, Skoog L, Rutqvist LE, et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 2005;7:R284–90.
   PubMed Web of Science ®Google Scholar
• Wegman P, Elingarami S, Carstensen J, Stål O, Nordenskjöld B, Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007;9:R7.
   PubMed Web of Science ®Google Scholar
• Lundin KB, Henningson M, Hietala M, Ingvar C, Rose C, Jernström H. Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients. Br J Cancer 2011;105:1676–83.
   PubMed Web of Science ®Google Scholar
• Bågeman E, Ingvar C, Rose C, Jernström H. Coffee consumption and CYP1A2*1F genotype modify age at breast cancer diagnosis and estrogen receptor status. Cancer Epidemiol Biomarkers Prev 2008;17:895–901.
   PubMed Web of Science ®Google Scholar
• Flockhart DA. Drug interactions: Cytochrome P450 drug interaction table: Indiana University School of Medicine (2007). [updated 2012 Jan 25; cited 2013 Apr 20]. Version 5.0 of the table released 2009-01-12. Available from: http://medicine.iupui.edu/clinpharm/ddis/table.aspx.
   Google Scholar
• Blake MJ, Gaedigk A, Pearce RE, Bomgaars LR, Christensen ML, Stowe C. et al. Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther 2007;81:510–6.
   PubMed Web of Science ®Google Scholar
• Rae JM, Sikora MJ, Henry NL, Li L, Kim S, Oesterreich S, et al. Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J 2009;9:258–64.
   PubMed Web of Science ®Google Scholar
• Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst 2011;103:489–500.
   PubMed Web of Science ®Google Scholar
• Ahern TP, Pedersen L, Cronin-Fenton DP, Sorensen HT, Lash TL. No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol Biomarkers Prev 2009; 18:2562–4.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007;101:113–21.
   PubMed Web of Science ®Google Scholar
• Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The breast international group 1-98 trial. J Natl Cancer Inst 2012;104:441–51.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez- Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007;116:496–526.
   PubMed Web of Science ®Google Scholar
• Walsky RL, Gaman EA, Obach RS. Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 2005;45:68–78.
   PubMed Web of Science ®Google Scholar
• Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 2009;70:1688–97.
   PubMed Web of Science ®Google Scholar
• Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007;25:5187–93.
   PubMed Web of Science ®Google Scholar
• Jernström H, Bågeman E, Rose C, Jönsson P-E, Ingvar C. CYP2C8 and CYP2C9 polymorphisms in relation to tumor characteristics and early breast cancer related events among 652 breast cancer patients. Br J Cancer 2009;101: 1817–23.
   PubMed Web of Science ®Google Scholar
• Simonsson M, Söderlind V, Henningson M, Hjertberg M, Rose C, Ingvar C, et al. Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status. Cancer Causes Control 2013;24:929–40.
   PubMed Web of Science ®Google Scholar